FDA Approves Vowst (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

CAMBRIDGE, Mass.& HOBOKEN, N.J.--(BUSINESS WIRE)--Apr. 26, 2023-- Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of Vowst (fecal microbiota...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news